EVMN 8-K 2026-10-01
Evommune, Inc. (EVMN) 8-K dated 2026-10-01 — accession 0001193125-26-409865.
Evommune, Inc. (EVMN) common stock.
Evommune, Inc. filed a 8-K on 2026-10-01. Accession 0001193125-26-409865.
This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported EVMN revenue for 2025-12-31 was $13.0M. Net income was -$68.9M. Revenue was up 85.7% from 2024-12-31 to 2025-12-31. EVMN currently screens at market cap $290.3M.
Not investment advice. The EVMN SEC hub lists recent forms. The stock page is the research view.